Brief: Volition Announces Expansion Of Availability Of The Nu.Q Vet Cancer Test Through Idexx's Reference Laboratory Network
12/01/2023 13:56
Jan 12 (Reuters) - VolitionRX Ltd VNRX.A :
* VOLITION ANNOUNCES EXPANSION OF AVAILABILITY OF THE NU.Q®
VET
CANCER TEST THROUGH IDEXX'S REFERENCE LABORATORY NETWORK
Source text for Eikon: ID:nPn2Pm82ja
Further company coverage: VNRX.A
((reuters.briefs@thomsonreuters.com;))
Recent news on VolitionRX
See all newsBrief: Volitionrx -Files Preliminary Prospectus For 10,006,360 Shares Of Common Stock Offered By Selling Stockholder - SEC Filing
Brief: Volitionrx - Advances Nu.Q Nets Platform Towards Commercialization
Brief: VolitionRX Limited Announces First Quarter 2026 Financial Results
Brief: Volition Reports Breakthrough In Liquid Biopsy Achievement Of Over 99% Purity In Isolating Cancer Dna
Brief: Volition Announces First Ever Automated Nu.Q® Vet Cancer Test With Fujifilm Vet Systems